[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201390117A1 - Композиция антител к vegfr-3 - Google Patents

Композиция антител к vegfr-3

Info

Publication number
EA201390117A1
EA201390117A1 EA201390117A EA201390117A EA201390117A1 EA 201390117 A1 EA201390117 A1 EA 201390117A1 EA 201390117 A EA201390117 A EA 201390117A EA 201390117 A EA201390117 A EA 201390117A EA 201390117 A1 EA201390117 A1 EA 201390117A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
vegfr
composition
diseases
treatment
Prior art date
Application number
EA201390117A
Other languages
English (en)
Other versions
EA023331B1 (ru
Inventor
Бронислав Пытовски
Кришнадатт Персауд
Натали Зайек
Original Assignee
Имклон Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390117(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Имклон Ллк filed Critical Имклон Ллк
Publication of EA201390117A1 publication Critical patent/EA201390117A1/ru
Publication of EA023331B1 publication Critical patent/EA023331B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предлагает моноклональные антитела к VEGFR-3, фармацевтические композиции, содержащие указанные антитела, и применение указанных антител для лечения заболеваний.
EA201390117A 2010-09-07 2011-09-01 Композиции антител к vegfr-3 EA023331B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07
PCT/US2011/050131 WO2012033696A1 (en) 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions

Publications (2)

Publication Number Publication Date
EA201390117A1 true EA201390117A1 (ru) 2013-06-28
EA023331B1 EA023331B1 (ru) 2016-05-31

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390117A EA023331B1 (ru) 2010-09-07 2011-09-01 Композиции антител к vegfr-3

Country Status (25)

Country Link
US (2) US8481034B2 (ru)
EP (1) EP2614081B1 (ru)
JP (1) JP2013538813A (ru)
KR (1) KR20130042601A (ru)
CN (1) CN103080133A (ru)
AR (1) AR082641A1 (ru)
AU (1) AU2011299443B2 (ru)
BR (1) BR112013005423A2 (ru)
CA (1) CA2809375C (ru)
CL (1) CL2013000607A1 (ru)
CO (1) CO6690754A2 (ru)
CR (1) CR20130065A (ru)
DO (1) DOP2013000039A (ru)
EA (1) EA023331B1 (ru)
EC (1) ECSP13012481A (ru)
ES (1) ES2568801T3 (ru)
GT (1) GT201300058A (ru)
MA (1) MA34487B1 (ru)
MX (1) MX2013002718A (ru)
PE (1) PE20131328A1 (ru)
SG (1) SG188265A1 (ru)
TW (1) TWI413527B (ru)
UA (1) UA109148C2 (ru)
WO (1) WO2012033696A1 (ru)
ZA (1) ZA201300804B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
JP6854765B2 (ja) * 2015-01-15 2021-04-07 オンコクエスト ファーマシューティカルズ インコーポレイテッド 標的への抗癌剤の送達を増加させる方法
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219419T2 (de) * 2001-01-19 2007-08-16 Ludwig Institute For Cancer Research Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체

Also Published As

Publication number Publication date
AU2011299443B2 (en) 2014-06-05
PE20131328A1 (es) 2013-11-18
CL2013000607A1 (es) 2014-04-11
US20130280278A1 (en) 2013-10-24
TWI413527B (zh) 2013-11-01
CO6690754A2 (es) 2013-06-17
ECSP13012481A (es) 2015-03-31
US8784818B2 (en) 2014-07-22
KR20130042601A (ko) 2013-04-26
MA34487B1 (fr) 2013-08-01
US8481034B2 (en) 2013-07-09
WO2012033696A1 (en) 2012-03-15
GT201300058A (es) 2014-07-16
TW201223543A (en) 2012-06-16
CA2809375A1 (en) 2012-03-15
BR112013005423A2 (pt) 2016-06-07
CA2809375C (en) 2016-02-09
ZA201300804B (en) 2014-07-30
SG188265A1 (en) 2013-04-30
ES2568801T3 (es) 2016-05-04
CR20130065A (es) 2013-03-21
UA109148C2 (ru) 2015-07-27
MX2013002718A (es) 2013-05-01
EA023331B1 (ru) 2016-05-31
CN103080133A (zh) 2013-05-01
AR082641A1 (es) 2012-12-19
EP2614081B1 (en) 2016-03-16
EP2614081A1 (en) 2013-07-17
US20120058126A1 (en) 2012-03-08
JP2013538813A (ja) 2013-10-17
DOP2013000039A (es) 2013-04-15
AU2011299443A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
CY1123145T1 (el) Anti-cd40 αντισωματα
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201791186A1 (ru) Антитела к cd38
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491505A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA202193044A2 (ru) Способы лечения таупатии
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201400579A1 (ru) Антитела к il-36r
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
PH12017500864A1 (en) Anti-notch1 antibodies
EA201401204A1 (ru) Антитела к il-23p19
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA201370018A1 (ru) Составы рифаксимина и их применение
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201200999A1 (ru) Способы лечения рака молочной железы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU